Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 26 September 2025 - 11 October 2025

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Metric Merck (MRK) Last Price (10/10/25) $86.02 Marketbeat Market Cap $215B Marketbeat P/E (TTM) ~13× Marketbeat Yield 3.8% Marketbeat 52-Week Range $73.31 – $111.58 Marketbeat YTD Total Return -11.07% Financecharts Q2 2025 Sales $15.8B Investing 2024 Sales $64.2B Merck 2024 R&D Spend $17.9B Merck Analyst PT (avg) $104 (12-mo) Marketbeat Consensus Rating Hold Marketbeat Company Overview Merck & Co. (MRK, called…
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases Protagonist Inc. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers…
11 October 2025
····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approved Reuters. By then, the landscape may include other new NASH therapies (possibly Lilly’s or Madrigal’s), but Novo’s combination strategy could set it apart. Wolfe Research…
9 October 2025
·
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Current News & October 2025 Updates EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan (PIP) for Acurx’s lead drug, ibezapolstat, in Clostridioides difficile infection Investing. This essentially means European regulators agree with Acurx’s plan to study ibezapolstat in children, a prerequisite for future marketing approval in Europe. As…
8 October 2025
····
Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Puerto Rico’s pharmaceutical roots and the Section 936 story For much of the late 20th century, Puerto Rico was an unlikely but critical component of America’s medicine chest. The island’s status as a U.S. territory provided access to federal intellectual‑property protections, Food and Drug Administration (FDA) oversight and the “Made in USA” label—all while offering costs and tax advantages more akin to…
6 October 2025
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

2025 Year‑to‑Date Stock Performance Cidara’s stock has been among the best performers in biotech. According to YTDReturn.com, a US$10,000 investment on 31 Dec 2024 would have grown to ~US$37,943 by 3 Oct 2025 because the share price increased from US$26.88 to US$101.99, a 279.43 % YTD return Ytdreturn. Zacks similarly reported a 217.8 % YTD rally by late September Nasdaq, reflecting further gains in October. The…
4 October 2025
·····
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Company Overview and Recent Developments Tarsus Pharmaceuticals (NASDAQ: TARS) is a biopharma focused on eye care. Its flagship product XDEMVY (lotilaner ophthalmic solution) was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis (eyelid inflammation caused by Demodex mites) Globenewswire. Tarsus reports that XDEMVY’s launch has exceeded expectations – CEO Bobak Azamian called the Q2 results their “strongest quarter to date”…
3 October 2025
····
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Stock Performance and Trends Sarepta’s stock is recovering some ground after steep losses. As of Oct 2, 2025, SRPT closed at $19.57, up about 6.8%for the day Investing. This followed a general uptrend in recent weeks: SRPT is up roughly 16% over the last month Marketbeat (though still down >80% from early 2025 levels). Trading volume has been moderate (0.6 million on Oct 2 vs.…
2 October 2025
····
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

What Is “TrumpRx”? A Direct-to-Consumer Drug Website “TrumpRx” is a planned federal website that will let Americans buy prescription medicines directly from the government at cash prices. According to administration officials, TrumpRx will negotiate discounted rates with drugmakers and allow patients to pay out-of-pocket for certain drugs, bypassing insurers and middlemen Wbtv Reuters. White House Press Secretary Karoline Leavitt confirmed…
30 September 2025
··
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 Reuters. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 Reuters). Its trailing P/E is 12.64× Reuters (ex. special items) and forward P/E ~7.7× Reuters, compared to ~19× for J&J and ~12× for Merck (see table). Pfizer’s dividend yield (~7.2%) Reuters is by far…
30 September 2025
···
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

Market Overview On Monday, Europe’s stock markets built on last week’s Fed-inspired optimism. Investors cheered a mix of corporate news and the prospect of more US rate cuts. Britain’s FTSE 100 climbed roughly 0.5%, putting it near record highs, and the STOXX 600 closed about +0.2% Reuters. France’s CAC 40 and Germany’s DAX each gained a few tenths of a…
29 September 2025
····
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Stock Price Performance (YTD & Recent) Crinetics stock has been volatile but trending upward in 2025, with the recent FDA catalyst propelling it sharply higher. On September 26, 2025, CRNX closed around $45–$46, up roughly +28% in a single day Reuters. This spike followed the Palsonify approval news and likely a short squeeze, given the high short interest (~14 million…
26 September 2025
···
1 … 42 43 44 45

Stock Market Today

  • Four Seasons Education (NYSE:FEDU) Shares Tumble 30% Amid Mixed Growth Signals
    January 22, 2026, 6:48 AM EST. Shares of Four Seasons Education (Cayman) Inc. (NYSE:FEDU) have plunged 30% in the past month, continuing a difficult 27% decline over the last year. Despite a seemingly attractive price-to-earnings (P/E) ratio of 13.5x, below the U.S. market average of roughly 20x, the company's uneven earnings growth raises concerns. After a striking 323% earnings per share increase last year, the firm showed no growth across the past three years, suggesting inconsistent performance. This lag behind the broader market's projected 16% expansion likely explains the low P/E and wary investor sentiment. The sharp stock drop reflects caution about the company's future growth prospects, signaling that its current valuation more so captures investor apprehension than undervaluation.
Go toTop